When it comes to looking for growth bargains, companies in some sort of technological field often come to mind. Here are three that I think could make nice candidates for the coming years, although theyre not without risk:
Nanoco Group (LSE: NANO) is an intriguing proposition. To quote the company itself, Nanoco leads the world in the research, development and large-scale manufacture of heavy-metal free quantum dots and semiconductor nanoparticles for use in displays, lighting, solar energy and bio-imaging.
The company has a patented technology for making these little doodahs on a large scale, and the demand for the LCDs in which theyre used can surely only grow especially as rules restricting toxic heavy metals are imposed.
Now, Nanoco is not expected to record a profit until July 2016, with forecasts suggesting a P/E of 65 for that year on todays 109p share price and there are quite a few shorters out there. I wouldnt buy right now, but Ill be examining this years results.
Proteome Sciences (LSE: PRM) develops protein and peptide markers for clinical use, including the diagnosis of things like Alzheimers, stroke and cancer. Thats clearly a technology with great potential, but again were looking at a company thats not yet in profit.
Results for 2014 released in May showed a 9% rise in revenue and told us of strong underlying growth in biomarker services. And though the year ended with a post-tax loss of 3.6m, chairman Christopher Pearce said he expects to see strong growth in revenue and news flow in 2015. With no profit forecast yet its hard to value the 27p shares, but Proteome is worth keeping an eye on.
Vislink (LSE: VLK), a company that develops advanced video technology for the media, law enforcement and defence markets, has not grown as quickly as some earlier investors had hoped. But at 60p the shares have still trebled in five years and have gained 32% in the past 12 months. After a steady climb since the start of 2015, could we be heading for a golden period?
Vislink recorded its first profit in 2012, and by 2014 it beat expectations with an adjusted operating profit of 7.2m from revenue of 61.9m and paid a decent dividend too. At the time of the report in May, chairman John Hawkins reckoned that 2014 had been a transformation year. And with forecasts putting the shares on a P/E of 12.5 this year, dropping to 11.4 next, there might be a transformation in investors rewards, too.
If you want another great growth idea, check out our hot new report that identifies 1 Top Small-Cap Stock From The Motley Fool. It’s a smaller company that has already rewarded its shareholders with a stonking performance, yet the Motley Fool’s top analysts reckon there could be a further 45% upside to come.
Want to know the name of this potential small-cap winner? Just click here to get your completely free report today.
Alan Oscroft has no position in any shares mentioned. The Motley Fool UK has no position in any of the shares mentioned. We Fools don’t all hold the same opinions, but we all believe that considering a diverse range of insights makes us better investors.